Literature DB >> 11753670

The human papillomavirus E6 protein and its contribution to malignant progression.

F Mantovani1, L Banks.   

Abstract

The human papillomavirus (HPV) E6 protein is one of three oncoproteins encoded by the virus. It has long been recognized as a potent oncogene and is intimately associated with the events that result in the malignant conversion of virally infected cells. In order to understand the mechanisms by which E6 contributes to the development of human malignancy many laboratories have focused their attention on identifying the cellular proteins with which E6 interacts. In this review we discuss these interactions in the light of their respective contributions to the malignant progression of HPV transformed cells.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11753670     DOI： 10.1038/sj.onc.1204869

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  150 in total

1.  RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells.

Authors:  Allison H S Hall; Kenneth A Alexander
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Lack of canonical E6 and E7 open reading frames in bird papillomaviruses: Fringilla coelebs papillomavirus and Psittacus erithacus timneh papillomavirus.

Authors:  Masanori Terai; Rob DeSalle; Robert D Burk
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Human papillomavirus type 8 E6 oncoprotein inhibits transcription of the PDZ protein syntenin-2.

Authors:  Daliborka Lazić; Martin Hufbauer; Paola Zigrino; Stephanie Buchholz; Siamaque Kazem; Mariet C W Feltkamp; Cornelia Mauch; Gertrud Steger; Herbert Pfister; Baki Akgül
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.

Authors:  Clara Bodelon; Svetlana Vinokurova; Joshua N Sampson; Johan A den Boon; Joan L Walker; Mark A Horswill; Keegan Korthauer; Mark Schiffman; Mark E Sherman; Rosemary E Zuna; Jason Mitchell; Xijun Zhang; Joseph F Boland; Anil K Chaturvedi; S Terence Dunn; Michael A Newton; Paul Ahlquist; Sophia S Wang; Nicolas Wentzensen
Journal:  Carcinogenesis       Date:  2015-12-09       Impact factor: 4.944

5.  Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.

Authors:  Kristi L Berger; Felicia Barriga; Michael J Lace; Lubomir P Turek; Gideon J Zamba; Frederick E Domann; John H Lee; Aloysius J Klingelhutz
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

6.  Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator.

Authors:  Noor Gammoh; Helena Sterlinko Grm; Paola Massimi; Lawrence Banks
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

Review 8.  Regulation of apoptosis by the papillomavirus E6 oncogene.

Authors:  Ting-Ting Li; Li-Na Zhao; Zhi-Guo Liu; Ying Han; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

9.  Increased incidence of squamous cell carcinomas in Mastomys natalensis papillomavirus E6 transgenic mice during two-stage skin carcinogenesis.

Authors:  Iris Helfrich; Min Chen; Rainer Schmidt; Gerhard Fürstenberger; Annette Kopp-Schneider; David Trick; Hermann-Josef Gröne; Harald Zur Hausen; Frank Rösl
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.